Sales Support
U.S.:+1-415-871-0703
U.K.:+44-203-289-4040
AUS.: +61-2-4786-0457
INDIA:+91-848-285-0837
Contact Us
We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
Healthcare and Pharmaceuticals industry

Anti-epileptic Drugs for Pediatrics market 2020 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2026

  • Purchase Options

 

Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Anti-epileptics drugs for pediatrics treatment are expected to experience visible shifts in terms of demand and adoption owing to factors such as rise in global prevalence of epilepsy, increasing healthcare spending and emergence of efficacious newer anti-epileptic drugs. Furthermore, co-morbidities associated with epilepsy such as depression and anxiety are on rise and major players are investing in the research and awareness programs for reduction of these co-morbidities along with epilepsy. For instance, Sanofi, S.A. invests major amounts into awareness programs in regions with emerging economies such as Latin America, Africa, and Asia Pacific. The company offers products with price adjustments in these regions to increase the access to these treatments. The investments by major players in the pipeline over the past few years have shown positive results in terms of product launches such as Vimpat drug approvals in Europe and Japan in the treatment of partial onset seizures for UCB Pharma in 2016.
Market Dynamics
Major market players are focusing on providing viable treatment options in patients suffering from refractory epilepsy or drug resistant epilepsy. The add-on or adjunctive therapies designed by market players offer significant positive results with relatively less side effects. This, in turn, is expected to boost the market growth rate for anti-epileptic drugs. Some notable drugs in the pipeline such as Lyrica (Pregabalin), are showing potential therapeutic effects with fewer drug interactions, improved side effect profiles, and enhanced overall safety. This addresses a major need in the AED market, since most of the older treatments such as carbamazepine, valproate, and phenytoin, although effective, have very poor safety profiles and are not well-tolerated by pediatric patients.
Market Taxonomy
This report segments the global Anti-Epileptic Drugs for Pediatrics Market on the basis of drug type and region. On the basis of drug type, the global Anti-Epileptic Drugs for Pediatrics Market is segmented into 1stgeneration, 2nd generation, and 3rd generation.
Key features of the study:
• This report provides in-depth analysis of Anti-Epileptic Drugs for Pediatrics Market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2016 - 2025), considering 2015 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global Anti-Epileptic Drugs for Pediatrics Market on the basis of the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Mylan N.V.*, Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc., Sanofi S.A., UCB Pharma Limited, Sunovion Pharmaceuticals Limited, Valeant Pharmaceuticals International, Inc., Zogenix, GW Pharmaceuticals, Insys, and Zynerba.
• Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global Anti-Epileptic Drugs for Pediatrics Market report caters to various stakeholders in this industry, including investors, suppliers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Anti-Epileptic Drugs for Pediatrics Market
Detailed Segmentation:
• Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
• Global Anti-Epileptic Drugs for Pediatrics Market, By Geography:
o North America
 U.S.
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Canada
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
o Europe
 U.K.
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Germany
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Italy
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 France
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Russia
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Rest of Europe
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
o Asia-Pacific
 China
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 India
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Japan
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 ASEAN
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Australia
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 South Korea
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Rest of Asia Pacific
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
o Latin America
 Brazil
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Mexico
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Rest of Latin America
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
o Middle East
 GCC
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Israel
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
o Africa
 North Africa
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 Central Africa
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
 South Africa
 By Drug Type:
 1st Generation
 2nd Generation
 3rd Generation
• Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profiles
 Mylan N.V.
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 Cephalon, Inc.
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 GlaxoSmithKline plc
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 Janssen Pharmaceuticals
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 Novartis AG
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 Pfizer, Inc.
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 Sanofi S.A.
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 UCB Pharma Limited
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 Sunovion Pharmaceuticals Limited
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 Valeant Pharmaceuticals International, Inc.
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 Zogenix
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 GW Pharmaceuticals
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 Insys
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
 Zynerba
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments/Updates
 Future Plans
o Analyst Views
• Section
o References
o Research Methodology
o About Us and Sales Contact
*Browse 23 market data tables and 43 figures on "Anti-Epileptic Pediatric Drugs Market - Global forecast to 2025".

Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
? Market Definition and Scope
o Executive Summary
? Market Snippet, By Drug Type
? Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
? Drivers
? Supply Side Drivers
? Demand Side Drivers
? Economic Drivers
? Restraints
? Market Opportunities
? Epidemiology
? Merger and Acquisitions
? PEST Analysis
? Pipeline Drug Analysis
? Recently Launched Drug Analysis
o Cost Tier Down Analysis
4. Global Anti-Epileptic Pediatric Drugs Market, By Drug Type, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o 1st Generation
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (USD Million)
o 2nd Generation
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (USD Million)
o 3rd Generation
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (USD Million)
5. Global Anti-Epileptic Pediatric Drugs Market, By Regions, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, By Region, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, For Regions, 2017 - 2025
o North America
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, By Country, 2017 - 2025
? U.S.
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Canada
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
o Europe
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, By Country, 2017 - 2025
? U.K.
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Germany
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Italy
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? France
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Russia
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Others
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
o Asia Pacific
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, By Country, 2017 - 2025
? China
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? India
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Japan
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? ASEAN
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Australia
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? South Korea
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Others
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
o Latin America
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, By Country, 2017 - 2025
? Brazil
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Mexico
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Others
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
o Africa
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, By Country, 2017 - 2025
? Northern Africa
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Central Africa
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? South Africa
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
o Middle East
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, By Country, 2017 - 2025
? GCC Countries
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Israel
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
? Others
? Country Trends
? Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
6. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profiles
? Mylan N.V.
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Cephalon, Inc.
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? GlaxoSmithKline plc
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Janssen Pharmaceuticals
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Novartis AG
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Pfizer, Inc.
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Sanofi S.A.
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? UCB Pharma Limited
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Sunovion Pharmaceuticals Limited
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Valeant Pharmaceuticals International, Inc.
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Zogenix
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? GW Pharmaceuticals
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Insys
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Zynerba
? Company Overview
? Drug Type Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
?
o Analyst Views
7. Section
o References
o Research Methodology
o About Us and Sales Contact
*Browse 23 market data tables and 43 figures on "Anti-Epileptic Pediatric Drugs Market - Global forecast to 2025".

 

  • Purchase Options

  • Happy To Assist You

Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.

Contact us